ADRA1 agonists(Adrenergic receptor alpha-1 agonists), ADRA2 agonists(Adrenergic receptors alpha-2 agonists), β1-adrenergic receptor agonists(Beta-1 adrenergic receptor agonists)

Therapeutic Areas

Otorhinolaryngologic DiseasesRespiratory Diseases

Active Indication

Nasal Obstruction

Inactive Indication

Congestion of nasal mucosaRhinitis, Allergic

Originator Organization

Merck Sharp & Dohme Corp.

Active Organization

Qinghai Lake Pharmaceutical Co. Ltd.

Inactive Organization

Schering-Plough Corp.

Drug Highest PhaseApproved

First Approval Date

US (30 Oct 1980),

Congestion of nasal mucosaRhinitis, Allergic

Regulation-

Structure

Molecular FormulaC10H17NO5S

InChIKeyXVPDSDYVNYOVMP-KXNXZCPBSA-N

CAS Registry7460-12-0

Clinical Trials associated with Pseudoephedrine Sulfate

NCT05692869 / CompletedNot Applicable

A Study to Investigate Continuous Blood Pressure Monitoring Using Traditional Device (ABPM) Versus Novel Devices (Biobeat and Aktiia)

The main purpose of this study in healthy participants is to find out whether the traditional ambulatory blood pressure monitor (ABPM) and newer wearable devices (EmbracePlus smartwatch device, Biobeat chest patch device, and Aktiia wrist device) will accurately pick up changes in blood pressure caused by 2 different medications (propranolol and pseudoephedrine). The study will last about 29 days excluding the screening period of 28 days.

Start Date31 Jan 2023

Sponsor / Collaborator

Eli Lilly & Co.

NCT05697328 / RecruitingNot ApplicableIIT

Pseudoephedrine Prophylaxis for Prevention of Middle Ear Barotrauma in Hyperbaric Oxygen Therapy

The purpose of this research is to study whether the use of pseudoephedrine can help prevent middle ear trauma during HBOT. Pseudoephedrine is an approved drug that is used for temporary relief of nasal or sinus pain and pressure.

Start Date31 Jan 2023

Sponsor / Collaborator

John Muir Health

ACTRN12622000542796 / CompletedPhase 2

Exploring the activity of pseudoephedrine in treating retrograde ejaculation following retroperitoneal lymph node dissection (RPLND) in survivors of testicular cancer - Part B

Start Date06 Sep 2022

Sponsor / Collaborator

Peter MacCallum Cancer Institute

100 Clinical Results associated with Pseudoephedrine Sulfate

100 Translational Medicine associated with Pseudoephedrine Sulfate

100 Patents (Medical) associated with Pseudoephedrine Sulfate

1,240

Literatures (Medical) associated with Pseudoephedrine Sulfate

01 Mar 2024·Journal of ethnopharmacology

Phytochemical profiling, toxicity studies, wound healing, analgesic and anti-inflammatory activities of Musa paradisiaca L. Musaceae (Plantain) stem extract in rats

Article

Author: Ijioma, Solomon Nnah ; Adurosakin, Oluwapelumi Eniola ; Uche, Mercylyn Ezinne ; Akubugwo, Emmanuel Iroha ; Ugbogu, Eziuche Amadike ; Emmanuel, Okezie ; Nosiri, Chidi Ijeoma ; Ekweogu, Celestine Nwabu

ETHNOPHARMACOLOGICAL RELEVANCE:

The stem of Musa paradisiaca (plantain) has found application in traditional medicine for the treatment of diabetes, inflammation, ulcers and wound injuries.

AIM OF THE STUDY:

This study investigated the phytochemical composition, toxicity profile, wound healing, anti-inflammatory and analgesic effects of aqueous Musa paradisiaca stem extract (AMPSE) in rats.

METHODS:

Phytochemical analysis of methanol-MPSE was performed by gas chromatography-mass spectrometry (GC-MS). Acute toxicity testing was carried out through oral administration of a single dose of AMPSE up to 5 g/kg. Four separate groups of rats were used for the subacute toxicity testing (n = 6). Group 1 served as a normal control and did not receive AMPSE, groups 2-4 received AMPSE daily by gavage for 28 days. In the experiments with excision and incision wounds, the rats were treated with 10 w/w AMPS extract. The anti-inflammatory and analgesic effects of AMPSE were assessed using egg albumin-induced paw oedema and acetic acid-induced writhing methods, respectively. For the subacute, anti-inflammatory and analgesic studies, AMPSE was administered to the experimental rats at doses of 300, 600 and 900 mg/kg body weight.

RESULTS:

Bioactive compounds identified include β-sitisterol, n-hexadecanoic acid, octadecanoic acid, diethyl sulfate, p-hydroxynorephedrine, phenylephrine, nor-pseudoephedrine, metaraminol, pseudoephedrine and vanillic acid. No signs of toxicity and no deaths were observed in all the groups. For the groups treated with AMPSE for 28 days, a significant reduction in alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, urea, sodium, chloride, total cholesterol, triglycerides, and low-density lipoprotein cholesterol were observed while high density lipoprotein cholesterol, glutathione and superoxide dismutase increased compared to control (p < 0.05). In wound healing experiments, AMPSE showed greater percent wound contraction and wound resistance fracture compared to the povidone-iodine (PI) treated and control groups. Treatment with 900 mg/kg AMPSE resulted in significant (p < 0.05) anti-inflammatory and analgesic effects compared to the control.

CONCLUSION:

This study shows that AMPSE is not toxic but contains biologically active compounds with hepatoprotective, anti-inflammatory, lipid-lowering and wound-healing effects. Treatment of rats with AMPSE has shown that AMPSE has anti-inflammatory, analgesic, hepatoprotective, lipid-lowering and wound-healing effects, supporting its therapeutic use in ethnomedicine.

01 Mar 2024·Journal of ethnopharmacology

Exploration of material basis: Chemical composition profile, metabolic profile and pharmacokinetic characteristics in Xingbei Zhike granule

Article

Author: Cao, Liang ; Hu, Guizhou ; Chen, Xialin ; Ren, Guoqing ; Wang, Zhenzhong ; Qian, Mengyu ; Gao, Xia ; Feng, Jian ; Dang, Huimin ; Xiao, Wei ; Wang, Jiajia ; Gao, Huifang

HEADINGS ETHNOPHARMACOLOGICAL RELEVANCE:

Xingbei Zhike granule (XBZK), a widely prescribed Chinese patent medicine, is known for its efficacy in clearing lung qi, relieving cough and reducing phlegm, as well as fever, dry and bitter taste, and irritability. Despite its clinical popularity, comprehensive investigations into its chemical composition, in vivo metabolism, and pharmacokinetic characteristics are limited.

AIM OF THE STUDY:

This study investigates the chemical composition, in vivo metabolism, and in vivo dynamics of XBZK to clarify its material basis and pharmacokinetic characteristics.

MATERIALS AND METHODS:

Ultra-high performance liquid chromatography with Orbitrap tandem mass spectrometry (UPLC-Orbitrap-MS) was used to determine the chemical composition and in vivo metabolic profile of XBZK. Additionally, UPLC with triple quadrupole mass spectrometry (UPLC-TQ-MS/MS) was performed to quantify its main components and evaluate its in vivo dynamics in rat plasma.

RESULTS:

In total, 57 components were identified in XBZK. Furthermore, 40 prototype components and 31 metabolites were detected in various biological matrices of rats, including plasma, tissues, bile, feces, and urine. After administration, the area under the curve (AUC) for ephedrine (Eph), pseudoephedrine (Peph), neotuberostemonine (Neo), amygdalin (Amy), and enoxolone (Eno) exhibited a strong linear relationship with the administered dose (r > 0.9) in all rats. And gender-related differences in the absorption of peiminine (Pmn), peimisine (Pms), and chrysin-7-O-glucuronide (Cog) were notable among rats, with male rats showing a dose-dependent pattern of absorption, while female rats exhibited minimal absorption.

CONCLUSIONS:

XBZK contains 57 components, primarily composed of flavonoids, alkaloids, and coumarins. The eight main components were rapidly absorbed and eliminated, with some, such as Eph, Peph, Neo, Amy and Eno, following a linear pharmacokinetic pattern. Furthermore, Pmn, Pms and Cog were well absorbed in male rats, showing a dose-dependent behavior.

01 Jan 2024·Journal of ethnopharmacology

Interpretation of the anti-influenza active ingredients and potential mechanisms of Ge Gen Decoction based on spectrum-effect relationships and network analysis

Article

Author: Geng, Zikai ; Ke, Siyuan ; Wang, Xiuyi ; Lyu, Jiantao ; Liu, Yu ; Li, Yaqun ; Liu, Xiyu

ETHNOPHARMACOLOGICAL RELEVANCE:

Ge Gen Decoction (GGD) is a classic traditional Chinese medicine (TCM) prescription that originated in the ancient Chinese medical book "Treatise on Febrile Diseases". The prescription consists of 7 herbs: Pueraria lobata (Willd.) Ohwi, Ephedra sinica Stapf, Cinnamomum cassia (L.) J.Presl, Paeonia lactiflora Pall., Glycyrrhiza uralensis Fisch., Zingiber officinale Rosc., and Ziziphus jujuba Mill. It can alleviate high fever and soreness in the neck and shoulders caused by exogenous wind chill and is widely used in both China and Japan. Currently, GGD is primarily utilized for treating flu and the common cold. GGD has been reported to show significant anti-influenza A virus (IAV) activity both in vitro and in vivo. However, the active ingredients responsible for its anti-influenza properties have not been elucidated, and the mechanisms underlying its anti-influenza effects require further research.

AIM OF THE STUDY:

This study aims to investigate the active ingredients and molecular mechanisms of GGD in treating influenza.

MATERIALS AND METHODS:

HPLC chromatograms were established for GGD water and different polar extracts. The effect of different GGD extracts on pulmonary virus titers and TNFα expression was assessed through RT-PCR analysis. Spectrum-effect relationships between chromatographic peaks of GGD and its virus inhibition rate and TNFα inhibition rate were investigated using partial least squares regression (PLSR) analysis. HPLC-Q-TOF-MS was utilized to identify the constituents absorbed into the blood after oral administration of GGD. Network analysis of the absorbed forms of active ingredients was conducted to predict the potential mechanisms of GGD. Subsequently, total SOD activity, CAT and HO-1 expression and Nrf2 nuclear translocation were then analyzed. Finally, the impact of interfering with HO-1 expression on the anti-IAV activity of GGD was examined.

RESULTS:

The study identified 11 anti-influenza active ingredients in GGD, which are daidzein, ononin, genistin, daidzin, 3'-methoxypuerarin, puerarin, pseudoephedrine, paeoniflorin, pormononetin-7-xylosyl-glucoside, penistein-7-O-apiosyl-glucoside, and ephedrine. Network analysis revealed various biological activities of GGD, including responses to ROS and oxidative stress. GGD also involves multiple antiviral pathways, such as hepatitis B, IAV, and Toll-like receptor pathways. Experimental assays demonstrated that GGD possesses independent antioxidant activity both in vitro and in vivo. In vitro, GGD inhibits the increase in intracellular ROS induced by IAV. In vivo, it reduces MDA levels and increases total pulmonary SOD activity. Applying siRNA and flow cytometry analysis revealed that GGD alleviates IAV-induced oxidative burst by promoting the expression of HO-1 and CAT. Western blot analysis revealed that GGD effectively promotes Nrf2 nuclear translocation and enhances Nrf2 expression. Furthermore, this study found that the enhancement of HO-1 expression by GGD contributed to its anti-IAV activity.

CONCLUSIONS:

The study identified the active ingredients of GGD against influenza and demonstrated the beneficial role of GGD's antioxidant activity in treating flu. The antioxidant activity of GGD is associated with the promotion of Nrf2 nuclear translocation and the upregulation of antioxidant enzymes such as SOD, HO-1, and CAT. Overall, this study provides evidence supporting the use of GGD as an adjunctive or complementary therapy for influenza.

News (Medical) associated with Pseudoephedrine Sulfate

28 Mar 2024

·www.prnewswire.com

U.S. News Reveals the 2024 Best OTC Medicine & Health Products

2024 edition includes 30+ new product categories evaluated, new dermatologist expert panel reviewers. WASHINGTON, March 28, 2024 /PRNewswire/ -- U.S. News & World Report, the global authority in health care rankings and consumer advice, today published the second annual Best OTC Medicine & Health Products. The latest edition of the rankings features 132 categories, with 33 brand new over-the-counter product categories included this year. The brands with the most No. 1 products among the 2024 rankings are Nature Made, followed by CeraVe and Neutrogena; the companies with the most No. 1 products are Kenvue Inc., followed by Haleon plc and Pharmavite LLC. "With hundreds of thousands of over-the-counter health products on the market in the U.S., the U.S. News annual Best OTC Medicine & Health Products rankings help consumers choose the best OTC products for themselves and their families," said Sumita Singh, general manager of Health at U.S. News. "Continuing our commitment to offer consumers trusted, data-backed ratings and rankings to help with their health care decisions, the 2024 evaluation features statistically 'best' brands evaluated by hundreds of pharmacists and dermatologists." In partnership with global market research firm The Harris Poll, U.S. News surveyed 354 pharmacists and 122 dermatologists practicing in the United States regarding 132 product categories such as adult and children's cough suppressants, men's and women's multivitamins, fish oil/omega-3 supplements, baby formula, face washes and cleansers, and retinol creams and serums. This was the first year that dermatologists were included in the survey, which was administered online in February 2024. To determine the rankings, panelists selected their top three recommended brands within each product category assigned to them. The brands that were highly ranked most often were ranked No. 1 for the corresponding product categories. U.S. News awarded the designations of Best OTC Medicine & Health Products only to those brands that satisfy U.S. News' statistical assessment of performance on the survey. Based on U.S. News' analysis, some product categories were awarded more than one winner. Some popular 2024 product category winners, ranked No. 1, evaluated by pharmacists include: Children's Cough Medicines: Children's Delsym Cough Drops: Halls Cough Suppressants: Delsym Decongestants, Oral: Sudafed (Pseudoephedrine) Diarrhea Medicines and Treatments: Imodium Eye Vitamins: Bausch + Lomb Ocuvite Fish Oil/Omega-3 Supplements: Nature Made Laxatives: MiraLAX Multivitamins for Men: Centrum Multivitamins for Women: One A Day Nausea Remedies: Dramamine Nausea Saline Nasal Sprays: Ayr Sore Throat Sprays: Chloraseptic Some popular 2024 product category winners, ranked No. 1, evaluated by dermatologists include: Eye Cream for Wrinkles: La Roche-Posay Face Moisturizers: CeraVe Face Washes and Cleansers: CeraVe Hand Creams: Neutrogena Moisturizers With SPF: CeraVe Night Creams: CeraVe Retinol Creams and Serums: Neutrogena Sunscreen for Face: EltaMD Vitamin C Serum: La Roche-Posay Vitamins for Hair Growth: Nutrafol Wrinkle Creams: Neutrogena Those looking to choose a health product that's right for them or their child should consult a medical professional as part of their decision-making process. For the full rankings, visit U.S. News' 2024 Best OTC Medicine & Health Products. Explore more of the 2024 product rankings using #BestOTCProducts on Facebook, Instagram, TikTok and X (formerly Twitter). About U.S. News & World Report U.S. News & World Report is the global leader in quality rankings that empower consumers, business leaders and policy officials to make better, more informed decisions about important issues affecting their lives and communities. A multifaceted digital media company with Education, Health, Money, Travel, Cars, News, Real Estate, Careers and 360 Reviews platforms, U.S. News provides rankings, independent reporting, data journalism, consumer advice and U.S. News Live events. More than 40 million people visit USNews.com each month for research and guidance. Founded in 1933, U.S. News is headquartered in Washington, D.C. About The Harris Poll The Harris Poll is a global consulting and market research firm that delivers proven intelligence for transformational times. Responsible for one of the longest-running surveys in the United States, Harris Poll provides unique context and social insights based on having analyzed public opinion, motivations, and social sentiment since 1963. It works with clients in three primary areas: building modern corporate reputation, crafting brand strategy and performance tracking, and data-driven thought leadership. It also delivers industry-leading healthcare insights expertise, specializing in research with patients, caregivers, nurses, physicians, specialists (across over 50 therapeutic areas) payers, hospital decision makers, policy makers, and pharmacists. Its mission is to provide insights and guidance to help leaders make the best decisions possible. To learn more, please visit . SOURCE U.S. News & World Report, L.P.

13 Sep 2023

·www.fiercepharma.com

It's unanimous: FDA panel says decongestant drug phenylephrine does not work

The FDA may soon remove over the counter use of a decongestant drug used in approximately 250 common cold and flu products because of its ineffectiveness. For decades, hundreds of oral decongestant products containing phenylephrine have been available in the United States over the counter. But on Tuesday, an FDA advisory committee agreed by a 16-0 vote that the ingredient does not work. Now it is up to the FDA to decide whether to ban over-the-counter use of widely used cold and flu decongestants such as Sudafed, Nyquil, Benadryl, Mucinex and Tylenol, which contain phenylephrine. Products that include the ingredient—roughly 250 of them—generated approximately $1.8 billion in sales in 2022, the FDA said. Data presented to the committee on Monday and Tuesday showed that phenylephrine performed no better than placebo in relieving congestion when given by mouth. Phenylephrine is designed to reduce the swelling of blood vessels but the committee concluded that when it is taken orally not enough of the drug reaches the nasal passages. “We clearly have better options in the over-the-counter space to help our patients, and the studies do not support that this is an effective drug,” Maria Coyle, chairwoman of the Nonprescription Drugs Advisory Committee (NDAC) and a professor of pharmacy at Ohio State University, said during meeting deliberations. Nasal sprays that contain phenylephrine are still effective, the FDA said. The drug also is effective for dilating the eyes and for use during surgery. Revoking phenylephrine’s OTC designation would be disruptive, forcing pharmacies to clear shelves of meds containing the ingredient and requiring companies to reformulate many of their cold and flu products. “The burdens created from decreased choice and availability of these products would be placed directly onto consumers and an already-strained U.S. healthcare system,” the Consumer Healthcare Products Association, said in a release. “The CHPA encourages the panel to consider the real-world experience and needs of consumers when making decisions that will have such broad implications.” Phenylephrine is one of two oral decongestants available without prescription. Sales of the other, pseudoephedrine, were restricted in 2006 because it can be misused to make methamphetamine. Products with pseudoephedrine are still available OTC but are often behind store counters or locked away, out of the reach of consumers. There also are limitations on how many pills that can be purchased in a store visit. The restrictions led to a boom in products containing phenylephrine. But soon after their rise in popularity, the FDA’s scrutiny of phenylephrine began. In 2007, the NDAC came to a similar conclusion on its ineffectiveness. While four subsequent studies showed the ineffectiveness of phenylephrine when taken as a pill, there was enough variability in the results to raise questions about how the studies were conducted. “We do believe that the original studies were methodologically unsound and do not match today’s standard,” Peter Starke, who first led the FDA’s review of phenylephrine, said to the committee. “By contrast, we believe the new data are credible and do not provide evidence that oral phenylephrine is effective.”

15 Dec 2022

·www.prnewswire.com

China Pharma Holdings, Inc. Announced that several products are included in the Catalogue of Medicines for People Infected with COVID-19

HAIKOU, China, Dec. 15, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced that its drugs were listed in The Catalogue of Medicines for People Infected with COVID-19 (First Edition) (hereinafter referred to as the Catalogue) published by People's Daily on December 12, 2022. Recently, China has completely ended its strict quarantine and zero case policies in response to COVID-19 pandemic in the past three years. Out of concern about the spread of the epidemic, people began to hoard many related drugs. The Chinese government has issued the Catalogue to guide people to take drugs accordingly. A series of drugs of our Company are listed in the catalog, and the demand is huge. Our modern Traditional Chinese Medicine (TCM) anti-virus product: Andrographolide has been listed in the Catalogue Our cold medicine: Naproxen Sodium and Pseudoephedrine Hydrochloride Sustained Release Tablets (brand name, Pusen OK), in which the compound ingredient pseudoephedrine is in line with the cold symptom relief medicine recommended in the Catalog It was announced in many places in China in recent days that pharmacies will no longer register or upload customer information on "four types of drugs", which includes anti-fever, cough, antiviral and antibiotic drugs. This will benefit the sales of our main products, roxithromycin and cefaclor The market demand for our masks has also increased significantly Ms. Li Zhilin, CEO of China Pharma said: " With the liberalization of epidemic risk control measures across China, the number of infected people may rise rapidly. The public's need in keeping certain epidemic prevention materials and related drugs has been dramatically increasing. As a professional pharmaceutical manufacturer for nearly 30 years, we will continue to spare no effort to provide high-quality products to protect people's health." About China Pharma Holdings, Inc. China Pharma Holdings, Inc. (NYSE American: CPHI) is a specialty pharmaceutical company that develops, manufactures, and markets a diversified portfolio of products, focusing on conditions with high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective business model is driven by market demand and supported by new GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit . The Company routinely posts important information on its website. Safe Harbor Statement Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties may include, but are not limited to: the achievability of financial guidance; success of new product development; unanticipated changes in product demand; increased competition; downturns in the Chinese economy; uncompetitive levels of research and development; and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations, except as required by applicable law or regulation. SOURCE China Pharma Holdings, Inc.

100 Deals associated with Pseudoephedrine Sulfate

External Link

KEGG	Wiki	ATC	Drug Bank
D05649	Pseudoephedrine Sulfate	R01BA02	DB00852

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Nasal Obstruction	CN	Qinghai Lake Pharmaceutical Co. Ltd.	01 Jan 1992
Congestion of nasal mucosa	US	Schering-Plough Corp.	30 Oct 1980
Rhinitis, Allergic	US	Schering-Plough Corp.	30 Oct 1980

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00704496 (CTgov)	Phase 3	Rhinitis \| Sleep	34	Pseudoephedrine (Placebo)	gmwvdqpoxw(piftafdnqd) = tmlwqgwvkn kmfmcahmdc (fwveryzrdz, ecxokjxiyt - gnyvipqinf) View more	-	18 Oct 2017
				Pseudoephedrine (Pseudoephedrine)	gmwvdqpoxw(piftafdnqd) = clguvrxpjm kmfmcahmdc (fwveryzrdz, tfpbokdnko - ofhullzqpn) View more
NCT01028014 (CTgov)	Not Applicable	-	56	Pseudoephedrine (Pseudoephedrine 120mg ER Daily)	zcqwrekdie(ogjehzmnte) = hpkokabrhv pysrtkmnfq (onokakdhhr, szxqkiaaqe - nzodesdutx) View more	-	05 Sep 2011
				Solifenacin (Solifenacin 5mg Daily)	zcqwrekdie(ogjehzmnte) = ukgwpqusdm pysrtkmnfq (onokakdhhr, szbkbpcxxa - smqvnurluv) View more
NCT00377403 (CTgov)	Phase 4	Acute respiratory infections \| Acute sinusitis	172	Saline spray (0.65%)+Pseudoephedrine Sustained Action+Acetaminophen+amoxicillin+guaifenesin+Dextromethorphan hydrobromide (Intervention Arm)	rnqhgahrwy(mctuigrzmh) = wbfpukdutd ckvyphpjez (qpbuilzpks, zluuxpcrjm - klzdcvstdm) View more	-	29 Jun 2011
				Saline spray (0.65%)+Pseudoephedrine Sustained Action+Acetaminophen+guaifenesin+Dextromethorphan hydrobromide (Symptomatic Treatments Only)	rnqhgahrwy(mctuigrzmh) = nhfaxpgywy ckvyphpjez (qpbuilzpks, ezrcglpfxs - mcgeilmwtt) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis